Metagenomi Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Emeryville, CA
MGX chart
What traders are saying about $MGX
Latest postsMetagenomi Therapeutics, Inc. news
- Metagenomi Therapeutics: Q3 Earnings Snapshot
Yahoo Finance ·
- Metagenomi Therapeutics 3Q 2026: Revenue $2.18M, EPS ($0.56) — 10-Q Summary
TradingView ·
- Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
Yahoo Finance ·
- FDA clears application for a first human trial of a one-time hemophilia A treatment
Stock Titan ·
- Metagenomi Therapeutics, Inc. (MGX) Seasonal returns chart
Yahoo Finance Australia ·
- Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
Yahoo Finance ·
- A potential one-time hemophilia A treatment is planned for a global trial in 2027, pending regulatory clearance.
Stock Titan ·
- Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
Yahoo Finance ·
- Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
Yahoo Finance ·
- Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates
Yahoo Finance ·
- Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Yahoo Finance ·
- Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
Yahoo Finance ·
Metagenomi Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $25.2M | $52.3M | $44.8M |
| Net income | -$87.9M | -$78.1M | -$68.3M |
| Diluted EPS | $-2.36 | $-2.36 | $-20.05 |
| Total assets (year end) | $221.1M | $324.6M | $364.8M |
| Cash and equivalents (year end) | $41.7M | $27.4M | $140.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Metagenomi Therapeutics, Inc.
- Ticker
- MGX (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Emeryville, CA
- Fiscal year end
- December 31
- SEC CIK
- 1785279
- Former names
- Metagenomi, Inc., Metagenomi Technologies, LLC
Frequently asked questions
What exchange is Metagenomi Therapeutics, Inc. listed on?
Metagenomi Therapeutics, Inc. trades on the Nasdaq under the ticker symbol MGX.
What industry is Metagenomi Therapeutics, Inc. in?
Metagenomi Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Metagenomi Therapeutics, Inc. headquartered?
Metagenomi Therapeutics, Inc.'s business address on file with the SEC is in Emeryville, CA.
When does Metagenomi Therapeutics, Inc.'s fiscal year end?
Metagenomi Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Metagenomi Therapeutics, Inc. report?
Metagenomi Therapeutics, Inc. reported $25.2M in revenue for calendar year 2025, according to its SEC filings.